semaglutide 2.4 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial calorie diet semaglutide 2.4 mg weekly step

The hypothesis is attractive, and the EVOKE data strengthen it, but it is not settled, and two problems deserve attention

Lozenges: Like oral drops, they contain the same active ingredients as the brand name GLP-1s but are produced by compounding pharmacies and are not approved by the FDA

(1) It also regenerates other antioxidants like vitamin E, enhancing the skins resilience against UV rays and pollutants

Results showed that oral semaglutide has a significantly higher efficacy compared to placebo and other DPP4 inhibitor drugs (53)

That being said, there is no significant clinical evidence to support its long-term safety, nor is it FDA-approved

Growth, body composition, and nutritional status in children and adolescents with Crohns disease